New Targeted Cancer Drug Advances to Global Phase 3 Trial…

New Targeted Cancer Drug Advances to Global Phase 3 Trial for Biliary Tract Cancer TALMedora Health Desk A promising experimental cancer therapy developed in Japan has reached a major milestone after receiving regulatory alignment from the U.S. Food and Drug Administration (FDA) and advancing directly into a global Phase 3 clinical trial. The investigational drug, nanvuranlat (JPH203), is being developed as a potential treatment for patients with advanced biliary tract cancer, a rare but highly aggressive cancer with limited treatment options once initial therapies stop working. Researchers believe the drug could offer a new targeted approach for patients whose disease has progressed after first-line treatment. Biliary tract cancers include cancers of the bile ducts and gallbladder. Although relatively uncommon, they are often diagnosed at advanced stages when curative surgery is no longer possible. Even when patients initially respond to chemotherapy, many experience disease progression, leaving few effective treatment options. Globally, oncologists continue to identify second-line therapies capable of extending survival while maintaining quality of life. This unmet need has driven interest in novel treatment approaches such as nanvuranlat. Unlike conventional chemotherapy, nanvuranlat targets a biological pathway that many cancers depend on for growth and survival. The drug inhibits L-type Amino Acid Transporter 1 (LAT1), a protein found at elevated levels in numerous cancer cells. Cancer c